Werewolf Therapeutics
HOWL
46 hedge funds and large institutions have $78M invested in Werewolf Therapeutics in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 16 closing their positions.
0.19% more ownership
Funds ownership: 68.79% → 68.98% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 49 → 46 (-3)
7% less capital invested
Capital invested by funds: $84.3M → $78M (-$6.25M)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.23M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$2.44M |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$1.12M |
| 4 |
Millennium Management
New York
|
+$942K |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$935K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.02M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.42M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$954K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$827K |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$825K |
HOWL Hedge Fund Activity: Q2 2022 in Review
46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2022, worth a combined $78M — down 7.4% from $84.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of HOWL and 14 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was PFM Health Sciences, adding an estimated $5.23M. The largest seller was BlackRock, cutting an estimated $5.02M.
- 46 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2022, down from 49 in Q1 2022.
- Funds reported $78M of Werewolf Therapeutics stock for Q2 2022, down 7.4% quarter-over-quarter.
- 14 funds opened new Werewolf Therapeutics positions in Q2 2022 and 16 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $5.23M added.
- The largest Werewolf Therapeutics seller in Q2 2022 was BlackRock, an estimated $5.02M sold.
Based on aggregated 13F filings for Q2 2022.